COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Expanded Access to Venetoclax

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03123029
Expanded Access Status : Available
First Posted : April 21, 2017
Last Update Posted : January 5, 2021
Information provided by (Responsible Party):

Tracking Information
First Submitted Date April 18, 2017
First Posted Date April 21, 2017
Last Update Posted Date January 5, 2021
Descriptive Information
Brief Title Expanded Access to Venetoclax
Official Title Expanded Access to Venetoclax
Brief Summary This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma
  • Acute Myeloid Leukemia (AML)
  • Non-Hodgkin's Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Amyloidosis
  • Plasma Cell Leukemia
Intervention Drug: Venetoclax
Venetoclax will be administered orally.
Other Names:
  • ABT-199
  • GDC-0199
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Eligibility Criteria

Inclusion Criteria:

  • The participant must not be eligible for a venetoclax clinical trial.
  • Pediatric participants may be evaluated on a case by case basis.
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Contact: ABBVIE CALL CENTER 844-663-3742
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03123029
Other Study ID Numbers C16-431
C19-920 ( Other Grant/Funding Number: AbbVie )
Responsible Party AbbVie
Study Sponsor AbbVie
Collaborators Not Provided
Study Director: AbbVie Inc. AbbVie
PRS Account AbbVie
Verification Date January 2021